Comparative Pharmacology
Head-to-head clinical analysis: ACETIC ACID W HYDROCORTISONE versus EOHILIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETIC ACID W HYDROCORTISONE versus EOHILIA.
ACETIC ACID W/ HYDROCORTISONE vs EOHILIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetic acid exerts antibacterial and antifungal activity by lowering pH and disrupting microbial cell membranes. Hydrocortisone is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
1 applicatorful (approximately 5 g) of the cream or ointment (containing 2% acetic acid and 1% hydrocortisone) inserted intravaginally once or twice daily for 7 days.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
None Documented
None Documented
Acetic acid: not applicable; hydrocortisone: plasma half-life ~1.5 hours (biologic half-life 8–12 hours). Due to low systemic absorption from topical application, systemic half-life is clinically irrelevant.
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
Acetic acid: minimal systemic absorption; hydrocortisone: hepatic metabolism, renal excretion of metabolites (<5% unchanged). Less than 10% of applied dose excreted in urine as metabolites; biliary/fecal excretion negligible.
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Category D/X
Category C
Corticosteroid
Corticosteroid